A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
NCT06102525
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
DRUG:
RZ-001
COMBINATION_PRODUCT:
VGCV
Sponsor
Rznomics, Inc.